Janine Nuver, MD PhD

Position: MD
Contact: email
Phone number: +31 (0)50 361  1173
Publications: Pubmed

Biography

Dr. Janine Nuver, MD PhD, is a medical oncologist at the department of Medical Oncology of the UMCG. She studied medicine in Groningen. In 2005, she obtained her PhD degree with the thesis ‘Chemotherapy-related vascular toxicity. Studies in germ cell tumour patients’. After her training in Internal Medicine and Medical Oncology, she was appointed staff membership at the department of Medical Oncology of the UMCG in 2013. During her Dutch Cancer Foundation (KWF) fellowship (2012), which had cancer survivor care as a focus, she visited the Radium Hospital in Oslo and Memorial Sloan-Kettering Cancer Center in New York. Research collaboration was established during her stay. At the department of Medical Oncology of the UMCG she is involved in various studies investigating late effects of cancer treatment. Furthermore, she is working on the implementation of survivorship care and the establishment of a ‘late effects clinic’ and multidisciplinary survivor consultation.

Research focus

Late effects of cancer treatment, survivorship care, psychosocial effects, cardiovascular disease, endocrine health, shared care follow-up, testicular cancer, breast cancer

Group Members

Involvement in research projects of:

• Lars Steggink - PhD student
• Sjoukje Lubberts - PhD student

Collaborations

• Prof. S.D. Fosså, medical oncologist, Radium Hospital, Oslo
• Dr. K. Oeffinger, primary care physician, Director of Adult Long-Term Follow-Up Program, MSKCC, New York
• Dr. M. Schaapveld, epidemiologist, NKI-AVL

Projects in which Janine Nuver is involved

• KWF grant RUG 2000-2177: Increased cardiovascular morbidity in patients cured from disseminated testicular cancer: What is the pathogenesis and how can it be prevented.
• Risico inschatting van ernstige bleomycine longtoxiciteit door bleomycine combinatie chemotherapie bij testiskanker patiënten met behulp van het bleomycine hyrdrolase gen polymorfismse.
• Pink Ribbon grant 2012 WO 39.C143: Cardiovascular morbidity and mortality in breast cancer survivors: identifying high risk subgroups.
• KWF grant 2011-5209: A case-cohort study to identify risk factors for cardiovascular disease in testicular cancer survivors.

Selected Publications

• Boer H, Nuver J, Lefrandt JD, Duijzer AW, Bunskoek S, Berendsen AJ, Siesling S, Gietema JA.Easy navigating through the forest of survivorship care. J Clin Oncol. 32:61-2, 2014.
• Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, Horwich A, Beyer J, Kataja V; ESMO Guidelines Working Group.Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24 Suppl 6:vi125-32, 2013.
• Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Claßen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germá Lluch JR, Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LH, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 24:878-88, 2013.
• Altena R, Hummel YM, Nuver J, Smit AJ, Lefrandt JD, de Boer RA, Voors AA, van den Berg MP, de Vries EG, Boezen HM, Gietema JA.Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. Ann Oncol. 22:2286-93, 2011.
• Nuver J, Oosting SF, Gietema JA.[Issues around testicular carcinoma]. Ned Tijdschr Geneeskd. 155:A4092, 2011. Dutch.
• Nuver J , de Haas EC, van Zweeden M, Gietema JA, Meijer C. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep. 23:247-53, 2010.
• Altena R, de Haas EC, Nuver J, Brouwer CA, van den Berg MP, SMit AJ, Postma A, Sleijfer DT, Gietema JA. Evulation of sub-acute changes in cardiac fucntion after ciplatin-based combination chemotherapy for testicular cancer. Br J Cancer. 100:1861-6, 2009.
• de Bruin D, de Jong IJ, Arts EG, Nuver J, Dullaart RP, Sluiter WJ, Hoekstra HJ, Sleijfer DT, Gietema JA.Semen quality in men with disseminated testicular cancer: relation with human chorionic gonadotropin beta-subunit and pituitary gonadal hormones. Fertil Steril. 91:2481-6, 2009.
• de Haas EC, Zwart N, Meijer C, Nuver J, Boezen HM, Suurmeijer AJ, Hoekstra HJ, van der Steege G, Sleijfer DT, Gietema JA.Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin Oncol. 26:1817-23, 2008.
• van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PT, Schimmel EC, Aleman BM, van Leeuwen FE.Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 24:467-75, 2006.
• Nuver J, Smit AJ, van der Meer J, van den Berg MP, van der Graaf WT, Meinardi MT, Sleijfer DT, Hoekstra HJ, van Gessel AI, van Roon AM, Gietema JA. Acute chemotehrapy-induced cardiovacsular changes in patients with testicular cancer. J Clin Oncol . 23:9130-7, 2005.
• Nuver J, Smit AJ, Wolffenbuttel BH, Sluiter WJ, Hoekstra HJ, Sleijfer DT, Gietema JA.The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol. 23:3718-25, 2005.
• Nuver J , Lutke Holzik MF, van Zweeden M, Hoekstra HJ, Meijer C, Suurmeijer AJ, Groen HJ, Hofstra RM, Sluiter WJ, Groen H, Sleijfer DT, Gietema JA. Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients. Pharmacogenet Genomics.15:399-405, 2005.
• Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, van den Berg MP, Hoekstra HJ, Sluiter WJ, Gietema JA. Left ventricular and cardiac autonomic function in survivors of testicular cancer.Eur J Clin Invest . 35:99-103, 2005.
• Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, van den Berg MP, Burgerhof JG, Hoekstra HJ, Sluiter WJ, Gietema JA.Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer. 40:701-6, 2004.
• de Vos FY, Nuver J, Willemse PH, van der Zee AG, Messerschmidt J, Burgerhof JG, de Vries EG, Gietema JA.Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage. Eur J Cancer. 40:696-700, 2004.
• Nuver J, van den Belt-Dusebout AW, Gietema JA.Long-term survivors of acute lymphoblastic leukemia. N Engl J Med. 349:1973, 2003.
• Nuver J , Gietema JA. [Thromboembolic complications during cisplatin-containing chemotherapy for testicular cancer: a problem in the short and possibly also the long term]. Ned Tijdschr Geneeskd. 147:428-30, 2003. Dutch.
• Nuver J, Smit AJ, Postma A, Sleijfer DT, Gietema JA.The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures. Cancer Treat Rev. 28:195-214, 2002.